199 related articles for article (PubMed ID: 32257246)
1. Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study).
Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simic D; Skride A; Tang W; Trusz-Gluza M; Vesely J; Vishnepolsky T; Vrabec M
Open Heart; 2020; 7(1):e001202. PubMed ID: 32257246
[TBL] [Abstract][Full Text] [Related]
2. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
Choi EK; Lee YS; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D; Oh YS
Open Heart; 2020 Nov; 7(2):. PubMed ID: 33184127
[TBL] [Abstract][Full Text] [Related]
3. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simić D; Skride A; Tang W; Trusz-Gluza M; Vesely J
J Thromb Thrombolysis; 2021 Nov; 52(4):1195-1206. PubMed ID: 33929686
[TBL] [Abstract][Full Text] [Related]
4. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D
Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666
[TBL] [Abstract][Full Text] [Related]
5. Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study.
Lee CW; Liu ME; Lee TM; Chang RY; Huang CY; Hu YF; Yeh HI
J Chin Med Assoc; 2021 Apr; 84(4):375-382. PubMed ID: 33784265
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
9. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
Stabile E; Izzo R; Rozza F; Losi MA; Coscioni E; Trimarco B
High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):115-22. PubMed ID: 27207360
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
11. Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients.
Kooistra HA; Piersma-Wichers M; Kluin-Nelemans HC; Veeger NJ; Meijer K
Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):388-94. PubMed ID: 27329860
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
13. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB
J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Vlacho B; Giner-Soriano M; Zabaleta-Del-Olmo E; Roso-Llorach A; García-Sangenís A; Morros-Pedrós R
Eur J Clin Pharmacol; 2017 Oct; 73(10):1323-1330. PubMed ID: 28725983
[TBL] [Abstract][Full Text] [Related]
15. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
17. Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
Pallisgaard JL; Gislason GH; Torp-Pedersen C; Lee CJ; Sindet-Pedersen C; Staerk L; Olesen JB; Lindhardt TB
PLoS One; 2016; 11(8):e0161768. PubMed ID: 27560967
[TBL] [Abstract][Full Text] [Related]
18. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
Giner-Soriano M; Casajuana M; Roso-Llorach A; Vedia C; Morros R
Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
[TBL] [Abstract][Full Text] [Related]
20. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
Stam-Slob MC; Connolly SJ; van der Graaf Y; van der Leeuw J; Dorresteijn JAN; Eikelboom JW; Peters RJG; Alings M; Visseren FLJ
Circulation; 2019 Jun; 139(25):2846-2856. PubMed ID: 31046423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
